AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27225596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (portion-controlled prepackaged foods)
Number of subjects: 183
Study 25783434 — intervention group
Group type: EXPERIMENTAL
Intervention: Online theory-based intervention to improve GFD adherence over six weeks
Number of subjects: 74
Study 22395054 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 45
Study 22395054 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control group)
Number of subjects: 45
Study 21813912 — intervention group
Group type: EXPERIMENTAL
Intervention: NO(2) Platinum (12 g/day)
Number of subjects: 24
Study 21813912 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 24
Study 19103500 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g bolus before skin incision and 400 mg/h during surgery)
Number of subjects: 100
Study 19103500 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 100
Study 16982564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular coil placement
Number of subjects: 20
Study 16982564 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous intrathoracal placement
Number of subjects: 20
Study 16982564 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous extrathoracal placement
Number of subjects: 20
Study 15229419 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient care
Number of subjects: 82
Study 15229419 — intervention group
Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 82
Study 11209950 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative recognition test
Number of subjects: 0
Study 11209950 — intervention group
Group type: EXPERIMENTAL
Intervention: Old item recognition test
Number of subjects: 0
Study 9265991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine treatment for allergic cough
Number of subjects: 20
Study 8500308 — intervention group
Group type: EXPERIMENTAL
Intervention: New method of estimation for analyzing compliance in randomized trials
Number of subjects: 0
Study 8500308 — intervention group
Group type: COMPARATOR
Intervention: Standard intent-to-treat analysis
Number of subjects: 0
Study 3404638 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose heparin (mean 13,200 +/- 2200 U per dose, APTT 1 1/2 times control)
Number of subjects: 75
Study 3404638 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose heparin (5000 U subcutaneously twice daily)
Number of subjects: 75
Study 30346496 — intervention group
Group type: COMPARATOR
Intervention: Standard PIL (e.g., 'Common, 1 in 10 people will be affected')
Number of subjects: 203
Study 30346496 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively framed PIL (e.g., 'Uncommon, 90% of people will not be affected')
Number of subjects: 203
Study 30346496 — intervention group
Group type: COMPARATOR
Intervention: Standard PIL
Number of subjects: 203
Study 29284810 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 53
Study 29284810 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 53
Study 29284810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 53
Study 25785768 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone drain (SD)
Number of subjects: 200
Study 25785768 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl chloride drain (PVCD)
Number of subjects: 200
Study 24093853 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding rates among women (8.2%)
Number of subjects: 10006
Study 24093853 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding and 30-day mortality association among men
Number of subjects: 10006
Study 24093853 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding and 30-day mortality association among women
Number of subjects: 10006
Study 24093853 — intervention group
Group type: EXPERIMENTAL
Intervention: Landmark analysis of 120-hour survivors
Number of subjects: 10006
Study 21167315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy + AcuNav intracardiac ultrasound + NavX electroanatomic mapping
Number of subjects: 74
Study 21167315 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy only
Number of subjects: 74
Study 18292676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide with 30% oxygen
Number of subjects: 70
Study 18292676 — intervention group
Group type: COMPARATOR
Intervention: Air with 30% oxygen
Number of subjects: 70
Study 16539047 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher density annulus of macular pigment
Number of subjects: 0
Study 16539047 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal distribution of macular pigment
Number of subjects: 0
Study 16539047 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxwell's spot
Number of subjects: 0
Study 16539047 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape of the foveal depression
Number of subjects: 0
Study 12760589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg 8 hourly for two weeks
Number of subjects: 10
Study 12760589 — intervention group
Group type: COMPARATOR
Intervention: Placebo for two weeks
Number of subjects: 10
Study 10857950 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (AHT) with enalapril or metoprolol
Number of subjects: 30
Study 10857950 — intervention group
Group type: COMPARATOR
Intervention: No antihypertensive treatment (AHT)
Number of subjects: 30
Study 8904862 — intervention group
Group type: EXPERIMENTAL
Intervention: No missed opportunities intervention (changing practice policy to screen and vaccinate eligible children at all visits)
Number of subjects: 1988
Study 8904862 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization reminder cards attached to medical charts
Number of subjects: 1988
Study 8904862 — intervention group
Group type: EXPERIMENTAL
Intervention: No missed opportunities intervention
Number of subjects: 1988
Study 8904862 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1988
Study 2053757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 1 or 2 g of oxacillin before surgery, followed by four days of oral oxacillin (3 g per day).
Number of subjects: 209
Study 2053757 — intervention group
Group type: COMPARATOR
Intervention: Control group without the use of prophylactic antibiotics.
Number of subjects: 209
Study 7049344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal therapy with methotrexate, hydrocortisone, and cytosine arabinoside plus cranial radiation (2400 rad over 2 1/2 weeks)
Number of subjects: 0
Study 7049344 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal therapy with methotrexate, hydrocortisone, and cytosine arabinoside without cranial radiation
Number of subjects: 0
Study 30200774 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-informed care (TIC) intervention
Number of subjects: 0
Study 30200774 — intervention group
Group type: COMPARATOR
Intervention: Delayed cohort (control)
Number of subjects: 0
Study 27440803 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 132
Study 27440803 — intervention group
Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 132
Study 26469916 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of wound exudate during dressing changes
Number of subjects: 18
Study 26469916 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without collection of wound exudate
Number of subjects: 18
Study 23950186 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Family Systems (IFS) intervention for 9 months
Number of subjects: 79
Study 23950186 — intervention group
Group type: COMPARATOR
Intervention: Education (control) group receiving mailed materials on RA symptoms and management
Number of subjects: 79
Study 21207054 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE + CAF (0.3 g kg(‐1) day(‐1) of creatine for 5 days and followed by 6 mg kg(‐1) of caffeine)
Number of subjects: 12
Study 21207054 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE + PLA (0.3 g kg(‐1) day(‐1) of creatine for 5 days then followed by 6 mg kg(‐1) of placebo)
Number of subjects: 12
Study 21207054 — intervention group
Group type: COMPARATOR
Intervention: CON (no ergogenic aids)
Number of subjects: 12
Study 21207054 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE + CAF
Number of subjects: 12
Study 21207054 — intervention group
Group type: EXPERIMENTAL
Intervention: CRE + PLA
Number of subjects: 12
Study 18838101 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial control over aversive stimulation followed by loss of control and restitution of control
Number of subjects: 66
Study 18838101 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrollable stress
Number of subjects: 66
Study 18838101 — intervention group
Group type: COMPARATOR
Intervention: No prior control
Number of subjects: 66
Study 17502449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 301
Study 17502449 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 301
Study 15467309 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) at a dose of 2 microg/kg intranasally
Number of subjects: 15
Study 15467309 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 15
Study 11208820 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation with cisplatin, fluorouracil, and vinblastine; cisplatin 20 mg/m2/d on days 1-5 and 17-21, fluorouracil 300 mg/m2/d on days 1-21, vinblastine 1 mg/m2/d on days 1-4 and 17-20, radiotherapy 1.5-Gy fractions twice daily for 21 days to a total dose of 45 Gy.
Number of subjects: 100
Study 11208820 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (arm I).
Number of subjects: 100
Study 9577425 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite coated bicylindrical pins
Number of subjects: 21
Study 9577425 — intervention group
Group type: COMPARATOR
Intervention: Uncoated bicylindrical pins
Number of subjects: 21
Study 9577425 — intervention group
Group type: COMPARATOR
Intervention: Uncoated pins
Number of subjects: 21
Study 8148868 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 14
Study 3275909 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 35 micrograms plus ethynodiol diacetate 1 mg
Number of subjects: 266
Study 3275909 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 30 micrograms plus levonorgestrel 0.15 mg
Number of subjects: 266
Study 3275909 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 35 micrograms plus norethindrone 1 mg
Number of subjects: 266
Study 3275909 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 35 micrograms plus norethindrone 0.5 and 1 mg (biphasic)
Number of subjects: 266
Study 31492485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DX)
Number of subjects: 47
Study 31492485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31116358 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting mean arterial pressure using cerebral autoregulation monitoring during cardiopulmonary bypass (CPB)
Number of subjects: 199
Study 31116358 — intervention group
Group type: COMPARATOR
Intervention: Usual care (mean arterial pressure targets determined according to institutional practice)
Number of subjects: 199
Study 31116358 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting mean arterial pressure using cerebral autoregulation monitoring during CPB
Number of subjects: 199
Study 29176540 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCP)
Number of subjects: 24
Study 29176540 — intervention group
Group type: COMPARATOR
Intervention: Control group (not taking OCP)
Number of subjects: 24
Study 24711000 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 100mg/kg/day as intermittent intravenous infusion from day -6 to day +15
Number of subjects: 80
Study 24711000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24711000 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 80
Study 23902627 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum support video and/or hotline service
Number of subjects: 0
Study 23902627 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal work
Number of subjects: 0
Study 23902627 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned pregnancy
Number of subjects: 0
Study 23902627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to breastfeed
Number of subjects: 0
Study 23902627 — intervention group
Group type: EXPERIMENTAL
Intervention: Source of maternal emotional support
Number of subjects: 0
Study 21369770 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate literacy
Number of subjects: 605
Study 21369770 — intervention group
Group type: COMPARATOR
Intervention: Low literacy
Number of subjects: 605
Study 19185807 — intervention group
Group type: EXPERIMENTAL
Intervention: California Hospital Safety and Security Act (post-enactment period 1996-2001)
Number of subjects: 116
Study 19185807 — intervention group
Group type: COMPARATOR
Intervention: New Jersey hospitals (control group)
Number of subjects: 116
Study 16995478 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative IL-2 administration (19 patients)
Number of subjects: 39
Study 16995478 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group, 20 patients)
Number of subjects: 39
Study 12826247 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study 12826247 — intervention group
Group type: COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 0
Study 10964639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociobehavioral intervention
Number of subjects: 0
Study 10964639 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 10964639 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 0
Study 8636768 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone, cisplatin, and cytarabine (DHAP)
Number of subjects: 49
Study 8636768 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (carmustine, etoposide, cytarabine, and cyclophosphamide [BEAC]) followed by autologous bone marrow transplantation (ABMT)
Number of subjects: 49
Study 1619995 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg bolus followed by 0.04 mg/kg/h infusion)
Number of subjects: 9
Study 1619995 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study 6142030 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 7
Study 30955478 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational text messages about osteoporosis (daily for one month)
Number of subjects: 121
Study 30955478 — intervention group
Group type: COMPARATOR
Intervention: Educational text messages on frequently occurring cancers in women (control group)
Number of subjects: 121
Study 29461966 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes at 60% V . O2peak (30MI)
Number of subjects: 64
Study 29461966 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes at 80% V . O2peak (30HI)
Number of subjects: 64
Study 29461966 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 minutes at 60% V . O2peak (120MI)
Number of subjects: 64
Study 29461966 — intervention group
Group type: COMPARATOR
Intervention: Rested (CON)
Number of subjects: 64
Study 27206514 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 59
Study 27206514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 24305799 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% permethrin-impregnated underwear
Number of subjects: 73
Study 24305799 — intervention group
Group type: COMPARATOR
Intervention: Placebo underwear
Number of subjects: 73
Study 22166068 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia during labor (Group A)
Number of subjects: 128
Study 22166068 — intervention group
Group type: COMPARATOR
Intervention: No analgesia (Group B)
Number of subjects: 128
Study 20375102 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe renal dysfunction (C(cr) < 60)
Number of subjects: 1975
Study 20375102 — intervention group
Group type: COMPARATOR
Intervention: Normal renal function
Number of subjects: 1975
Study 20375102 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for history of hypertension
Number of subjects: 1975
Study 20375102 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for hypercholesterolemia
Number of subjects: 1975
Study 20375102 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for diabetes
Number of subjects: 1975
Study 20375102 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for smoking habits
Number of subjects: 1975
Study 20375102 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for physical activity status
Number of subjects: 1975
Study 19056011 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin α (activated) treatment
Number of subjects: 1
Study 19056011 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 1
Study 16162207 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus infection detection using PCR on plasma samples
Number of subjects: 263
Study 16162207 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplant
Number of subjects: 263
Study 16162207 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplant
Number of subjects: 263
Study 16162207 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplant
Number of subjects: 263
Study 16162207 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to viremia onset
Number of subjects: 263
Study 16162207 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms at time of viremia
Number of subjects: 263
Study 16162207 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery from adenovirus infection
Number of subjects: 263
Study 16162207 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent acute rejection
Number of subjects: 263
Study 14572189 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 180
Study 14572189 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 180
Study 14572189 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic beverage
Number of subjects: 180
Study 9473994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation services for 5 hours, 1 day per week, over 1 year
Number of subjects: 46
Study 9473994 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (nontreatment comparison group)
Number of subjects: 46
Study 7603811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension (20 mg/kg/day twice daily for 4 days)
Number of subjects: 308
Study 7603811 — intervention group
Group type: COMPARATOR
Intervention: Penicillin suspension (45 mg/kg/day divided three times daily for 10 days)
Number of subjects: 308
Study 2168908 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (19 patients followed for 16 months)
Number of subjects: 26
Study 2168908 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (7 patients with more advanced disease)
Number of subjects: 26
Study 638248 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 244
Study 638248 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+CT
Number of subjects: 244
Study 638248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal relapse
Number of subjects: 244
Study 638248 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow relapse
Number of subjects: 244
Study 638248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal disease
Number of subjects: 244
Study 638248 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow involvement
Number of subjects: 244
Study 31283796 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 60
Study 31283796 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 60
Study 28514299 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Number of subjects: 96
Study 28514299 — intervention group
Group type: COMPARATOR
Intervention: Parecoxib intravenous injection (Group A)
Number of subjects: 96
Study 28514299 — intervention group
Group type: COMPARATOR
Intervention: Oral celecoxib (Group B)
Number of subjects: 96
Study 26573452 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (20 intermittent presses to stimulate Large Intestine 4 and Spleen 6)
Number of subjects: 132
Study 26573452 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (20 intermittent presses to the patella and olecranon)
Number of subjects: 132
Study 26573452 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 132
Study 24205115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus CNCM I‐4036
Number of subjects: 100
Study 24205115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve CNCM I‐4035
Number of subjects: 100
Study 24205115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei CNCM I‐4034, Bifidobacterium breve CNCM I‐4035, Lactobacillus rhamnosus CNCM I‐4036
Number of subjects: 100
Study 24205115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21544022 — intervention group
Group type: EXPERIMENTAL
Intervention: SensaScope
Number of subjects: 24
Study 21544022 — intervention group
Group type: COMPARATOR
Intervention: Macintosh 3 laryngoscope
Number of subjects: 24
Study 18523893 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized advice and a dose tapering schedule
Number of subjects: 135
Study 18523893 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 135
Study 16557206 — intervention group
Group type: EXPERIMENTAL
Intervention: PET using fluorine-18 fluorodeoxyglucose (FDG)
Number of subjects: 151
Study 16557206 — intervention group
Group type: COMPARATOR
Intervention: Dual-head coincidence gamma camera (CGC-I)
Number of subjects: 151
Study 16557206 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging (CI)
Number of subjects: 151